Answers are grounded in this paper and cite their sources.
Since its approval by the Food and Drug Administration (FDA) in 1969 procarbazine has had an established role as a single agent in combination chemotherapy of Hodgkin's disease. The drug offers some benefits for patients with lymphomas of other than Hodgkin's type and small and large cell carcinomas of lung, but there has been no documented enlargement of the role of procarbazine beyond these applications during the past 5 years. Toxicities are hematologic and neurologic, and there are also potential adverse effects in multiple drug interactions and in possible carcinogenesis. Procarbazine should therefore be used only against malignant disease by clinicians experienced in its use and cognizant of potential adverse effects.
No takes yet. Share an insight, caveat, or question.
SAMUEL D. SPIVACK (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: